Therefore, patients with KIF5B-ALK rare fusion can flexibly combine the first-, second-, and third-generation ALK-TKIs for sequential therapy in combination with ALK fusion type and mutation type, so as to improve the prognosis of patients with ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.